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This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).SUMMARYThe recent identification of hemogenic endothelium (HE) in human pluripotent stem cell (hPSC) cultures presents opportunities to
investigate signaling pathways that are essential for blood development from endothelium and provides an exploratory platform for
de novo generation of hematopoietic stem cells (HSCs). However, the use of poorly defined human or animal components limits the util-
ity of the current differentiation systems for studying specific growth factors required for HE induction andmanufacturing clinical-grade
therapeutic blood cells. Here, we identified chemically defined conditions required to produce HE fromhPSCs growing in Essential 8 (E8)
medium and showed that Tenascin C (TenC), an extracellular matrix protein associated with HSC niches, strongly promotes HE and
definitive hematopoiesis in this system. hPSCs differentiated in chemically defined conditions undergo stages of development similar
to those previously described in hPSCs cocultured on OP9 feeders, including the formation of VE-Cadherin+CD73CD235a/CD43
HE and hematopoietic progenitors with myeloid and T lymphoid potential.INTRODUCTION
In the embryo, hemogenic endothelium (HE) has been
identified as an immediate direct precursor of hemato-
poietic progenitors and hematopoietic stem cells (HSCs)
(Bertrand et al., 2010; Boisset et al., 2010; Jaffredo et al.,
2000; Kissa and Herbomel, 2010; Zovein et al., 2008).
Thus, the ability to produce HE from human pluripotent
stem cells (hPSCs) is considered a critical step toward the
de novo generation of blood progenitors and stem cells.
The recent identification and characterization of HE in
hPSC cultures by our lab and others have provided a plat-
form for investigating pathways that control HE formation
and subsequent HSC specification (Choi et al., 2012; Ken-
nedy et al., 2012; Rafii et al., 2013). However, the use of
xenogeneic or allogeneic feeder cells, poorly defined serum
and matrix proteins, or proprietary medium and supple-
ments of undisclosed chemical composition limits the
utility of the current differentiation systems for studying
factors that are essential for HE development and specifica-
tion. Here, after plating hPSCs from a single-cell suspen-
sion in a completely chemically defined medium that
was free of serum components and xenogeneic proteins,
we identified a set of factors and matrix proteins that
are capable of supporting hematopoietic differentiation.
Importantly, we showed the critical role of the HSC niche
matrix component Tenascin C (TenC) in supporting theStem Cell Repdevelopment of hematoendothelial and T lymphoid cells
from hPSCs.
In our previous studies (Choi et al., 2012; Vodyanik
et al., 2006, 2010), we identified distinct stages of hema-
toendothelial development following hPSC differentiation
in coculture with OP9 (Figure 1). Plating hPSCs onto OP9
stromal cells induces the formation of primitive streak and
mesodermal cells that can be detected based on the ex-
pression of apelin receptor (APLNR) and the absence of
endothelial (CD31 and VE-cadherin [VEC]), endothelial/
mesenchymal (CD73 and CD105), and hematopoietic
(CD43 and CD45) cell-surface markers, i.e., by the EMHlin
phenotype (Choi et al., 2012; Vodyanik et al., 2010).
The early EMHlinAPLNR+ cells that appear in OP9 cocul-
ture on day 2 of differentiation express primitive posterior
mesoderm (PM) genes (T, MIXL1, FOXF1, and GATA2)
and display the APLNR+PDGFRa+KDR+ phenotype (here-
after referred to as A+P+ cells). These cells possess mesen-
chymoangioblast (MB) potential, i.e., the potential to
form colonies with the capacity to differentiate into
mesenchymal stem cells (MSC) and endothelial cells.
On day 3 of differentiation, A+P+ cells acquire blast (BL)-
CFC or hemangioblast (HB) potential (Vodyanik et al.,
2010). With advanced maturation, EMHlinAPLNR+ me-
sodermal cells lose BL-CFC activity, upregulate KDR,
and downregulate PDGFRa, i.e., they acquire the he-
matovascular mesodermal precursor (HVMP) phenotype,orts j Vol. 3 j 1073–1084 j December 9, 2014 j ª2014 The Authors 1073
Figure 1. Schematic Diagram of Hemato-
poietic Differentiation and the Specific
Markers and Functional Assays Used to
Identify Each Stage of Development
The main cell subsets observed in previous
differentiation studies using coculture with
OP9 feeders (Choi et al., 2012; Vodyanik
et al., 2006, 2010), and the current chem-
ically defined cultures using ColIV and
TenC matrices are shown. PM, primitive
posterior mesoderm; HVMP, hematovascular
mesodermal precursor; HEP, hemogenic
endothelial progenitors; AHP, angiogenic
hematopoietic progenitors; non-HEP, non-
hemogenic endothelial progenitors; HP,
hematopoietic progenitors; EMkP, eryth-
romegakaryocytic progenitors. EMHlin in-
dicates lack of expression of endothelial
(CD31 and VEC), endothelial/mesenchymal
(CD73 and CD105), and hematopoietic
(CD43 and CD45) markers. lin indicates
lack of expression of markers associated
with hematopoietic lineages. MB, mesen-
chymoangioblast; HB, hemangioblast.
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Khi cells). Khi HVMP cells downregulate the primitive
streak genes T andMIXL1, and upregulate genes associated
with lateral plate and hematovascular mesoderm develop-
ment (FOXF1, ETV2, and GATA2). Khi HVMPs are highly
enriched in cells with the potential to form hematoen-
dothelial clusters on OP9 (Choi et al., 2012). The first
endothelial cells that coexpress VEC and CD31 emerge
from Khi mesodermal cells by day 4 of differentiation.
The emerging VEC+ cells represent a heterogeneous popu-
lation that includes CD235a/CD43CD73+ nonhemo-
genic endothelial progenitors (non-HEPs) and CD235a/
CD43CD73 hemogenic endothelial progenitors (HEPs)
(Choi et al., 2012). HEPs lack hematopoietic CFC poten-
tial, but acquire it after coculture with stromal cells. The
first hematopoietic cells that express CD43 emerge within
the VEC+ cells on day 4–5 of differentiation. These cells ex-
press low levels of CD43 (CD43lo) and coexpress CD235a,
but lack CD41a expression, i.e., they have the phenotype
VEC+CD43lo235a+41a. Because these cells have the ca-
pacity to form hematopoietic colonies in the presence of
FGF2 and hematopoietic cytokines, as well as to form a
monolayer of endothelial cells on fibronectin, we desig-
nated them as angiogenic hematopoietic progenitors
(AHPs). The CD41a+ cells emerge within the CD235a+
population. These CD235a+CD41a+ cells are highly en-
riched in erythro-megakaryocytic progenitors and lack1074 Stem Cell Reports j Vol. 3 j 1073–1084 j December 9, 2014 j ª2014 Thendothelial potential. The progenitors with broad myelo-
lymphoid potential and the linCD34+CD43+CD45
phenotype can be detected in hPSC cultures shortly after
the emergence of CD235a+CD41a+ cells. Acquisition of
CD45 expression by lin cells is associated with progres-
sive myeloid commitment (Vodyanik et al., 2006). In the
present work, we demonstrated that a TenC-based, chem-
ically defined system is able to generate all mesodermal
and endothelial transitional stages and myelolymphoid
progenitors that we observed using the serum- and OP9
feeder-based differentiation system described above.
Because our differentiation system utilizes hPSCs growing
in chemically defined xenogene-free Essential 8 (E8) me-
dium on vitronectin (VTN) (Chen et al., 2011), it provides
the opportunity to produce clinical-grade endothelial and
myelolymphoid progenitors from hPSCs for therapeutic
purposes.RESULTS
IMDM/F12-Based Medium Is Essential for Efficient
Differentiation of hPSCs into Hematoendothelial
Lineages from a Single-Cell Suspension in 2D Culture
Previously, our lab developed an hPSC differentiation pro-
tocol for the efficient generation of hematopoietic progen-
itors using a coculture method on the mouse stromal celle Authors
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2007). Although the OP9 system supports efficient genera-
tion of HE and multilineage hematopoietic progenitors
(Figure 1), this system is very sensitive to variations in
serum quality, stromal cell maintenance, and the size of
the hPSC colonies and clumps used for differentiation
(Choi et al., 2011; Vodyanik and Slukvin, 2007). Forming
embryoid bodies (EBs) is another commonly used
approach for inducing HE and hematopoietic progenitors
from hPSCs (Kennedy et al., 2012; Ng et al., 2005, 2008;
Wang et al., 2004). However, EB methods often rely on
serum or undefined media and supplements, and also
have significant drawbacks, such as asynchronous differen-
tiation, high variability, and dependence on the initial
clump size. Additionally, inconsistency in the quality of
hPSCs caused by variations in the albumin batches used
for hPSC maintenance may lead to variations in the effi-
ciency of blood development.
To overcome these limitations, we set out to charac-
terize chemically defined media and matrix proteins
capable of supporting hematoendothelial differentiation
without serum from a single-cell suspension of H1 human
embryonic stem cells (hESCs) maintained in a completely
defined xenogene-free system using E8 medium on VTN
(Chen et al., 2011). First, we plated hESCs as single cells
and allowed them to attach for 24 hr in E8 medium sup-
plemented with 10 mM Rho kinase inhibitor on Matrigel
(MTG), VTN, or Collagen IV (ColIV) in normoxia. Then,
the medium was changed to either basal growth factor-
free mTeSR1, E8 (DF4S), E8 with an IMDM base (I4S), or
E8 with an IMDM/F12 base (IF4S) supplemented with hu-
man recombinant BMP4, FGF2, and VEGF factors, which
are commonly used to induce blood formation from
hPSCs (Pick et al., 2007; Salvagiotto et al., 2011). After
4 days of differentiation, the cell cultures were evaluated
for the presence of CD31+ cells, which coexpress KDR
and VEC and are highly enriched in hematoendothelial
progenitors (Choi et al., 2012). Flow-cytometric analy-
sis showed that the cells that differentiated on ColIV-
coated plates in IF4S differentiated most efficiently into
CD31+ hematoendothelial precursors (Figure S1 available
online). Later, we found that the addition of polyvinylal-
cohol, nonessential amino acids (NEAA), GlutaMAX,
chemically defined lipid concentrate, and monothiogly-
cerol increased cell viability and differentiation efficiency
(data not shown). The basal medium thus obtained is
referred to as IF9S (IMDM/F12 plus nine supplements;
see Table S1 for the complete composition of the me-
dium). These results demonstrated that the selected
medium and supplements made it possible to obtain
hematoendothelial cells in a chemically defined, xeno-
gene-free condition on ColIV matrix from hPSCs main-
tained in E8 medium.Stem Cell RepAnalysis of the Molecular Signatures of
Hematopoiesis-Supporting Stromal Cell Lines
Identified TenC as an Extracellular Matrix that Is
Uniquely Expressed in OP9 Feeders with High
Hematopoiesis-Inducing Potential
Previously, we showed that OP9 is superior to S17 andMS5
stromal cell lines for inducing hematopoietic differentia-
tion (Vodyanik et al., 2005). We also found that day 8 over-
grown OP9 cultures are superior to day 4 semiconfluent
OP9 cultures for inducing hematopoietic CFCs, including
multipotential GEMM-CFCs. The observation that the con-
fluency of the stromal cells has an effect on differentiation
efficiency suggested that an extracellular matrix influences
hematoendothelial differentiation. In order to find thema-
trix protein(s) that is critical for the hematopoiesis-support-
ing activity of OP9, we performed molecular profiling of
S17 and MS5 stromal cell lines with low hematopoiesis-
inducing potential. In addition, we compared overgrown
OP9 (day 8) with semiconfluent OP9 (day 4) monolayers.
Transcriptome analysis revealed 21 genes that showed at
least 3-fold higher expression in day 8 overgrownOP9 cells
as compared with all other stromal cells (Figure 2A). These
included genes encoding Ptn (pleiotrophin), a secreted
regulator of HSC expansion and regeneration (Himburg
et al., 2010); Rspo3 (R-spondin 3), an important regulator
ofWnt signaling and angioblast development (Kazanskaya
et al., 2008); and the extracellular matrix protein Postn
(periostin), which is required for B lymphopoiesis (Siewe
et al., 2011). Interestingly, one themost highly upregulated
genes in overconfluent OP9 was Tnc (TenC) (Figure 2B).
TenC is expressed by mesenchymal cells underlying he-
matopoietic clusters in the aorta-gonado-mesonephros
(AGM) region and is required for intraembryonic and post-
natal hematopoiesis (Marshall et al., 1999; Nakamura-Ish-
izu et al., 2012; Ohta et al., 1998). It is also expressed in
the bone marrow stem cell niche (Nakamura-Ishizu et al.,
2012). Because of these unique properties, we tested
whether TenC could support hematopoietic differentiation
more effectively than ColIV.
TenC Facilitates the Development of Mesoderm and
Hematoendothelial Precursors in Chemically Defined
Cultures following Stage-Specific Treatment of FGF2,
BMP4, Activin A, LiCl, VEGF, and Hematopoietic
Cytokines
In previous studies, we identified the major stages of hem-
atoendothelial development from hPSCs using the OP9
coculture system (Figure 1; Choi et al., 2012; Slukvin,
2013; Vodyanik et al., 2005, 2006, 2010). In order to repro-
duce the hematoendothelial development observed inOP9
coculture, we searched for the optimal combinations of
morphogens, growth factors, and extracellular matrices to
facilitate the stepwise progression of hPSC differentiationorts j Vol. 3 j 1073–1084 j December 9, 2014 j ª2014 The Authors 1075
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A B Figure 2. Comparison of Different Mouse
Stromal Cell Lines that Support Hemato-
poietic Differentiation or Maintenance
(A) Venn diagram revealing the number of
genes that were differentially expressed
among the stromal cell lines. d4, day 4; d8,
day 8.
(B) Heatmap of 21 genes uniquely upregu-
lated in overconfluent (d8) OP9 stromal cell
lines as compared with all other stromal cell
lines (S17, MS5, and semiconfluent OP9
[d4]). TenC (Tnc) is one of the top differ-
entially overexpressed genes in overgrown
OP9 cells.
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defined conditions.
During embryonic development, BMP4,Wnt, and TGFb/
Nodal/Activin A signaling pathways are critical for initi-
ating primitive streak formation and subsequent meso-
derm development (Gadue et al., 2005; Keller, 2005). It
has been shown that the activation of these signaling path-
ways is essential to induce the expression of brachyury (T)
and KDR (Flk-1, VEGFR2), and initiate mesodermal
commitment of mouse PSCs and hPSCs (Cerdan et al.,
2012; Kennedy et al., 2007; Nostro et al., 2008; Pearson
et al., 2008; Pick et al., 2007; Salvagiotto et al., 2011). We
found that high concentrations of BMP4 (50 ng/ml) com-
bined with low concentrations of Activin A (15 ng/ml)
and a supplement of LiCl (2 mM) consistently induced
expression of the mesodermal surface markers APLNR,
KDR, and PDGFRa after 2 days of culture of singularized
hESCs on ColIV or TenC, as described above. However,
these conditions poorly supported cell survival and
required the addition of FGF2 and a hypoxic condition
(5% O2, 5% CO2) to improve cell viability and output of
mesodermal cells. Day 2 mesodermal cells that differenti-
ated in these conditions expressed PDGFRa andAPLNR sur-
face markers, i.e., they became A+P+ cells and displayedMB
colony-forming potential (Figures 3A and 3C), similar to
what was observed for A+P+ mesodermal cells obtained
from day 2 hPSCs differentiated in OP9 coculture (Vodya-
nik et al., 2010). After 2 days of differentiation, we found
that only FGF2 and VEGF were sufficient for A+P+ meso-
derm to acquire HB potential on day 3 of differentiation.
Similarly to their counterparts generated in OP9 coculture,
day 3 A+P+ cells that were generated in chemically defined
conditions expressed TandMIXL1 primitive streak genes at
a high level, as well as FOXF1 andGATA2 lateral platemeso-1076 Stem Cell Reports j Vol. 3 j 1073–1084 j December 9, 2014 j ª2014 Thderm genes (Figure 3C). The pattern of development was
similar in cells cultured on ColIV and TenC. However, the
TenC cultures produced significantly more A+P+ cells and
MB and HB colonies (Figures 3A, 3B, and 3D).
We also found that only FGF2 and VEGF were sufficient
to advancemesoderm specification toward a hematovascu-
lar fate, as signified by the increase of KDR and decrease of
PDGFRa expression on day 4 of differentiation (Figures 3E
and S2). Similarly to Khi HVMP cells isolated form hPSC/
OP9 cocultures, KDRhiCD31 (Khi) cells obtained in chem-
ically defined conditions downregulated T and MIXL1 pri-
mitive streak genes and upregulated the genes FOXF1,
ETV2, and GATA2, which are associated with lateral plate
and hematovascular mesoderm development (Figure 3C).
Although day 4 differentiated cells lost HB potential (Fig-
ure 3D), Khi cells were capable of forming hematoendothe-
lial clusters when sorted and plated onto OP9 (Figure 3G).
In contrast, KDRlo (Klo) cells only formed endothelial clus-
ters with almost no hemogenic activity (Figure 3G). This is
also consistent with differentiation in OP9 coculture (Choi
et al., 2012). The percentage of Khi HVMP cells was consis-
tently higher in TenC cultures (Figure 3F).
Because the formation of HVMPs in hPSC/OP9 coculture
was closely followed by the development of HE and blood
progenitors, we supplemented our cultures with SCF, TPO,
IL-6, and IL-3 hematopoietic cytokines in addition to VEGF
and FGF2, starting from day 4 of differentiation. Although
we noticed that the continuous treatment of cultures with
FGF2 and VEGF was sufficient for induction of endothelial
progenitors and hematopoietic specification, the addition
of hematopoietic cytokines was essential to increase the
output of these cells in chemically defined cultures. On
day 5 of differentiation in these conditions, we observed
the three major subsets of the VEC+ population ase Authors
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VEC+CD235a/CD43CD73+ (non-HEPs), VEC+CD235a/
CD43CD73 (HEPs), and VEC+CD43/ CD235a+ (AHPs)
(Figures 4A and 4B). When these subsets were sorted and
plated in endothelial conditions, they all formed a mono-
layer of VEC-expressing cells with the capacity to uptake
AcLDL and form vascular tubes in the tube formation assay,
consistent with OP9 coculture (Figure 4C). However, he-
matopoietic CFC potential was mostly restricted to the
VEC+CD43/CD235a+ cells (Figure 4D). Importantly, similar
to our previous finding with day 5 VEC + subsets generated
in coculture with OP9, the hematopoietic CFC potential of
VEC+CD43/CD235a+ cells was detected only in serum-free
medium in the presence of FGF2 in addition to hematopoi-
etic cytokines (Figures 4D and S3). This indicates that
VEC+CD43/CD235a+ cells are essentially similar to the
AHPs identified in hPSC/OP9 coculture (Choi et al.,
2012). We previously defined HEPs as VEC+CD43CD73
cells that lack hematopoietic CFC potential but are capable
of acquiring it after culture on OP9 (Choi et al., 2012). To
determine whether VEC+CD43CD73 cells generated in
completely chemically defined conditions are similar to
HEPs produced in OP9 cocultures, we sorted the day 5
VEC+ subpopulations and cultured them on OP9 as previ-
ously described (Choi et al., 2012). In these conditions,
the HEPs formed both endothelial and hematopoietic cells
with a large number of HE clusters, whereas AHPs formed
predominantly hematopoietic cells with few endothelial
cells and hematoendothelial clusters. VEC+CD43CD73+
cells formed exclusively endothelial clusters, consistent
with the non-HEP phenotype (Figure 4C). Cultures that
differentiated on TenC had a larger population of total
CD31+ and VEC+ cells, and thus increased populations of
HEPs, non-HEPs, and AHPs compared with cultures differ-
entiated on ColIV (Figures 4A, 4B, and S4).
When numerous floating, round hematopoietic cells
became visible in cultures on day 6, the hypoxic conditions
were not necessary to sustain hematopoietic development.
Therefore, from day 6 of differentiation, the cultures were
transferred to a normoxic incubator (20% O2, 5% CO2).
By day 8 of differentiation, the cultures continued to
develop and expand the CD43+ hematopoietic cells,
which consisted of CD235a+CD41a+ cells enriched in er-
ythro-megakaryocytic progenitors and CD235a/CD41a
CD43+CD45/+ cells that expressed CD34 but lacked other
lineage markers (lin) (Figure 5). Consistent with cells that
differentiated on OP9, hematopoietic colony-forming
potential was limited to the CD43+ subpopulations (Fig-
ure 5C). CD43+ hematopoietic progenitors were generated
in significantly higher numbers on TenC compared with
ColIV (Figures 5A, 5B, and S4). In addition, the GEMM-
CFC potential was significantly greater in cultures on
TenC compared with those on ColIV (Figure 5D).Stem Cell RepTenC Is Superior to ColIV for Supporting
Hematopoietic Differentiation from a Variety of hPSC
Lines
Although we developed the differentiation protocol using
H1 hESCs, we found that the chemically defined condi-
tions described here also supported the formation of HE
and blood progenitors from another hESC line (H9) and
human induced pluripotent stem cells (hiPSCs) generated
from fibroblasts or bone marrow mononuclear cells (Fig-
ure S5). Previously, we demonstrated that hiPSCs obtained
through reprogramming of bonemarrowmononuclear cell
(BM) hiPSCs differentiated less efficiently into blood cells
on OP9 feeders compared with fibroblast-derived (FB)
hiPSCs (Hu et al., 2011). We reproduced that finding
when we differentiated BM and FB iPSCs on ColIV. How-
ever, differentiation on TenC restored the hematopoietic
differentiation potential of BM hiPSCs to the level seen
with hESCs and FB hiPSCs (Figure S5), thereby confirming
that TenC is superior to ColIV for promoting hematopoiet-
ic differentiation from hPSCs.
TenC Uniquely Supports Specification of T Lymphoid
Progenitors from hPSCs
To find out whether our culture system supports the estab-
lishment of the definitive hematopoietic program from
hPSCs, we analyzed the Tcell potential of blood cells gener-
ated in our system as an indicator of definitive hematopoi-
esis (Kennedy et al., 2012). When we collected CD43+
floating cells from day 9 differentiated cultures and re-
plated them onto OP9 expressing DLL4 (OP9-DLL4),
CD7+CD5+ lymphoid progenitors began to emerge by
week 2 of coculture. By week 3, CD4+CD8+ double-positive
T cells arose (Figure 6A). Interestingly, CD43+ cells gener-
ated on both ColIV and TenC had the capacity to generate
CD5+CD7+ lymphoid progenitors, although CD43+ cells
generated on ColIV had a significantly lower potential.
However, progression toward CD4+CD8+ T lymphoid cells
was consistently observed only fromCD43+ cells generated
on TenC, and not from ColIV cultures (Figure 6B). To
confirm T cell development, we analyzed the genomic
DNA of the hematopoietic cells from OP9-DLL4 cultures
for the presence of T cell receptor (TCR) rearrangements.
This analysis demonstrated the presence of multiple PCR
products of random V-J and D-J rearrangements at the b lo-
cus and V-J rearrangements at the g locus, indicative of a
polyclonal T lineage repertoire (Figures 6C and 6D). Over-
all, these findings signify that the extracellular matrix
protein TenC is essential for supporting the generation of
hematopoietic cells with myeloid and lymphoid potential
from hPSCs in chemically defined conditions. However,
we failed to obtain engraftment following transplanta-
tion TenC differentiated cells in immunocompromised
mice (data not shown), which suggests that additionalorts j Vol. 3 j 1073–1084 j December 9, 2014 j ª2014 The Authors 1077
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Figure 3. Mesodermal Development from H1 hESCs in Chemically Defined Conditions on ColIV and TenC
Cultures differentiated on ColIV versus TenC for 2, 3, and 4 days in chemically defined conditions.
(A and B) Flow-cytometry plots (A) and graphs (B) comparing the percentage of A+P+ primitive mesodermal population on days 2 and 3.
(C) Expression of mesoderm lineage genes measured by quantitative PCR and normalized to RPL13A, comparing day 3 P+ cells and day 4 Khi
cells.
(D) Comparison of the MB/HB colony-forming potential of day 2, day 3, and day 4 cultures.
(E and F) Flow-cytometry plots (E) and graphs (F) comparing the percentage of KDRhiCD31 (Khi) HVMP, CD31+, and KDRloCD31 (Klo)
populations on day 4 of differentiation.
(legend continued on next page)
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Figure 4. Major Subsets of VEC+ Cells
Generated after 5 Days of Differentiation
of H1 hESCs in Chemically Defined Condi-
tions on ColIV and TenC
(A) Flow-cytometric analysis demonstrates
major subsets of VEC+ progenitors generated
after 5 days of hESC culture in chemically
defined conditions on ColIV and TenC. Lower
dot plots show VEC+-gated cells.
(B) Percentages of VEC+ cells and subsets
generated in ColIV and TenC cultures. Error
bars are mean ± SE from at least three ex-
periments (*p < 0.01).
(C) Endothelial and hematopoietic po-
tential of day 5 VEC+ subsets. Progenitor
subsets sorted and cultured either in endo-
thelial conditions with subsequent tube
formation assay or on OP9 with immuno-
fluorescent and flow-cytometry results after
7 days. Dot plots show expression of VEC and
CD43 in TRA-1-85+-gated human cells. Scale
bars, 100 mM.
(D) CFC potential of an isolated VEC+ subset
in serum-free clonogenic medium con-
taining hematopoietic cytokines and FGF2.
Error bars are mean ± SE from three experi-
ments (*p < 0.01). Scale bar represents
100 mm. VEC was visualized using a sec-
ondary antibody conjugated to DyLight 488,
and CD43 was visualized using a secondary
antibody conjugated to DyLight 594.
See also Figures S3 and S4.
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program in hematoendothelial progenitors generated in
our system.DISCUSSION
During the last decade, significant progress has been made
in achieving hematopoietic differentiation from hPSCs.
Multiple protocols for hematopoietic differentiation have
been developed and havemade it possible to routinely pro-
duce blood cells for experimentation. However, generating
HSCs with long-term reconstitution potential from hPSCs
remains a significant challenge. Hematopoietic cells and
HSCs arise from a specific subset of endothelium (HE) in(G) Hematopoietic and endothelial potential of Khi and Klo cells isolat
Upper panels show flow cytometry of TRA-1-85+-gated human cells an
cocultures with Khi and Klo cells.
In (B)–(D) and (G), bars are mean ± SE from at least three experiments
secondary antibody conjugated to DyLight 488, and CD43 was visualiz
Figures S1 and S2.
Stem Cell Repthe embryo (Bertrand et al., 2010; Boisset et al., 2010; Jaf-
fredo et al., 2000; Kissa and Herbomel, 2010; Zovein
et al., 2008). Therefore, the ability to interrogate the
signaling pathways that induce HE specification and the
endothelial-to-hematopoietic transition in a completely
chemically defined environment is essential in order
to identify the factors required for HSC specification.
Although the original protocols for hematopoietic differ-
entiation employed xenogeneic feeder cells and/or serum,
several serum- and feeder-free systems for hematopoietic
differentiation have been described recently (Ng et al.,
2008; Salvagiotto et al., 2011; Smith et al., 2013; Wang
et al., 2012). However, these protocols still require serum
components (albumin) and it remains unclear whether
these protocols reproduce the distinct waves ofed from day 4 differentiated cells after coculture on OP9 for 7 days.
d lower panels show immunofluorescence staining of cells from OP9
(*p < 0.01). Scale bar represents 100 mm. VEC was visualized using a
ed using a secondary antibody conjugated to DyLight 594. See also
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Figure 5. Major Subsets of CD43+ Cells
Generated after 8 Days of Differentiation
of H1 hESCs in Chemically Defined Condi-
tions on ColIV and TenC
(A) Flow-cytometry analysis shows major
subsets of CD43+ cells generated in cultures
on ColIV and TenC. Lower dot plots show
CD43+-gated cells.
(B) Cultures on TenC produce more CD43+
cells.
(C) Hematopoietic CFC potential is limited
to the CD43+ subpopulations.
(D) Cultures differentiated on TenC produce
more CFCs than cultures differentiated on
ColIV.
In (B)–(D), error bars are mean ± SE from at
least three experiments (*p < 0.01). See also
Figure S5.
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Tenascin C Supports Hematopoiesis from hPSCshematopoiesis, including the generation of HE with defin-
itive lymphomyeloid potential, observed in the original
differentiation systems. Recently, Kennedy et al. (2012)
developed a feeder- and stroma-free condition for EB-based
hematopoietic differentiation in a proprietary medium
with undisclosed nutrient supplements from hPSCs ex-
panded on mouse embryonic fibroblasts. These conditions
reproduced primitive and definitive waves of hematopoie-
sis and generated HE with T lymphoid potential. Here, we
developed a protocol that enables the efficient production
of blood cells in completely chemically defined conditions,
free of serum and xenogeneic proteins, from a single-cell
suspension of hPSCs maintained in chemically defined
E8 medium (Chen et al., 2011). Our protocol eliminates
the variability associated with animal- or human-sourced
albumins, xenogenic matrices, clump size variation, and
asynchronous differentiation observed in EB systems.
It also reproduces the typical waves of hematopoiesis,
including the formation of HE and definitive hematopoiet-
ic progenitors, observed in hPSCs differentiated on OP9.
Importantly, based on molecular profiling of OP9 and
stromal cell lines with different hematopoiesis-inducing1080 Stem Cell Reports j Vol. 3 j 1073–1084 j December 9, 2014 j ª2014 Thactivity, we found that the TenC matrix protein, which is
uniquely expressed in OP9 with robust hemato-inducing
potential, strongly promotes hematoendothelial and T
lymphoid development from hPSCs. TenC is a disulfide-
linked hexameric glycoprotein that is mainly expressed
during embryonic development. Although TenC mostly
disappears in adult organisms, its expression is upregulated
during wound repair, neovascularization, neoplasia (Hsia
and Schwarzbauer, 2005), and limb regeneration (Stewart
et al., 2013). TenC is found in adult bone marrow, where
it is expressed predominantly in the endosteal region
(Klein et al., 1993; Soini et al., 1993). TenC supports the
proliferation of bone marrow hematopoietic cells (Seiffert
et al., 1998) and erythropoiesis (Seki et al., 2006). TenC-
deficient mice were shown to have lower bone marrow
CFC potential (Ohta et al., 1998), failed to reconstitute he-
matopoiesis after bone marrow ablation, and showed a
reduced ability to support engraftment of wild-type HSCs
(Nakamura-Ishizu et al., 2012). In addition, TenC is ex-
pressed in the thymus (Hemesath and Stefansson, 1994)
and plays an important role in T cell development, as
evidenced by decreased T lymphoid progenitors in thee Authors
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Figure 6. T Cell Potential of Hematopoi-
etic Cells Collected from H1 hESC Cultures
Differentiated for 9 Days in Chemically
Defined Conditions on either ColIV or
TenC
(A and B) Flow-cytometry analysis (A) and
percentages (B) of cells collected under
ColIV or TenC conditions after culture on
OP9-DLL4 for 3 weeks. Error bars are mean +
SE from at least three experiments (*p <
0.01).
(C and D) Analysis for TCR rearrangement by
genomic PCR. H1 T cells are T cells derived
from differentiating H1 hESCs on TenC, PB
control is peripheral blood (positive con-
trol), and H1 hESCs are undifferentiated H1
hESCs (negative control).
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marrow of TenC-deficient mice (Ellis et al., 2013). Interest-
ingly, high levels of TenC expression were also detected in
the human and chicken AGM region (Anstrom and Tucker,
1996; Marshall et al., 1999), the site where the first HSCs
emerge, and in hematopoietic sites of human fetal liver (Pa-
padopoulos et al., 2004). Because TenC expression is highly
enriched in the subaortic mesenchyme directly under-
neath hematopoietic clusters, it was suggested that TenC
plays a pivotal role in HSC development during embryo-
genesis (Marshall et al., 1999). TenC is also involved in
the regulation of angiogenesis and cardiac endothelial pro-
genitors (Ballard et al., 2006). Our studies demonstrated the
superior properties of TenC for promoting hematoendo-
thelial development from hPSCs. The positive effect of
TenC was obvious at all stages of differentiation, including
the enhancement of hematovascular mesoderm, HE, and
CD43+ hematopoietic progenitors. Importantly, TenC was
able to support the development of definitive hematopoi-
etic cells with T lymphoid potential, whereas we were not
able to obtain such cells in cultures on ColIV. The TenC
molecule is composed of an amino-terminal oligomeriza-
tion region followed by heptad repeats, EGF-like and fibro-
nectin type III repeats, and a fibrinogen globe (Hsia and
Schwarzbauer, 2005). Each of these domains interacts
with different surface receptors, including integrins a9b1,
avb3, and avb6, and toll-like receptor 4 (TLR-4) (Midwood
et al., 2011). It is believed that the effect and interaction of
TenC with cells requires the integrated action of multipleStem Cell Repdomains (Fischer et al., 1997), although several unique
mitogenic domains capable of inducing the proliferation
of hematopoietic cells were identified within this molecule
(Seiffert et al., 1998). The interaction of TenCwith a9b1 in-
tegrin plays a central role in TenC-mediated expansion of
hematopoietic stem and progenitor cells (Nakamura-Ishizu
et al., 2012) andmay be required for normal T cell develop-
ment (Ellis et al., 2013). Several signaling mechanisms
implicated in cell interaction with TenC have been identi-
fied, including the suppression of fibronectin-activated
focal adhesion kinase signaling, Rho-mediated kinase
signaling, and stimulation of Wnt signaling pathways (re-
viewed in Orend, 2005). Further studies to identify the
mechanism of TenC signaling on hPSCs and their hemato-
poietic derivatives would help elucidate the role of this ma-
trix protein during development. It is also important to
determine the developmental stages that are most affected
by TenC and clarify whether TenC simply enhances the
expansion of hemogenic populations or promotes hema-
toendothelial commitment.
In summary, the findings presented here identify the
TenC matrix protein, as well as completely chemically
defined conditions that are free of serum/serum compo-
nents and animal proteins and are capable of supporting
the scalable production of HE and definitive blood cells
fromhPSCs. This differentiation systemwill enable the pre-
cise interrogation of signaling molecules implicated in he-
matopoietic differentiation and provides a platform for
producing cGMP-grade blood cells for clinical application.orts j Vol. 3 j 1073–1084 j December 9, 2014 j ª2014 The Authors 1081
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hPSC Maintenance
hPSCs, WA01 (H1) and WA09 (H9) hESCs, the DF19-9-7T human
fibroblast iPSC line, and the IISH2i-BM9 bone marrow-derived
iPSC line (WiCell, Madison, WI) were maintained on VTN or
MTG in E8 medium supplemented with FGF2 and TGFb (Pepro-
tech). Cells were passaged when they reached 80% confluency us-
ing 0.5 mM EDTA in PBS. The cells were maintained in normoxic
conditions with 5% CO2.
hPSC Differentiation
Single-cell suspensions of hPSCs were obtained by treating the
hPSC cultures at 80% confluency with 13 TrypLE (Life Technolo-
gies). Single cells were plated at an optimized density ranging
from 5,000 cells/cm2 to 15,000 cells/cm2 (depending on the cell
line) onto six-well plates coated with 0.5 mg/cm2 of ColIV
(Sigma-Aldrich) or 0.5 mg/cm2 TenC (Millipore) in E8medium sup-
plementedwith 10 mMRho kinase inhibitor (Tocris Y-27632). After
24 hr (day 0), the mediumwas changed to IF9S medium (see Table
S1 for the complete composition of the medium) supplemented
with 50 ng/ml BMP4 (Peprotech), 15 ng/ml Activin A (Peprotech),
50 ng/ml FGF2 (Miltenyi Biotech), 2 mM LiCl (Sigma), and, on
occasion, 1 mM Rho kinase inhibitor to increase cell viability. On
day 2, the medium was changed to IF9S medium supplemented
with 50 ng/ml FGF2 and 50 ng/ml VEGF. On day 4, the medium
was changed to IF9S medium supplemented with 50 ng/ml
FGF2, VEGF, TPO, SCF, IL-6, and 10 ng/ml IL-3. On day 6, addi-
tional IF9S medium supplemented with the same six factors were
added to the cultures without aspirating the old medium. IF9S
(IMDM/F12 with nine supplements) was made in-house with the
following components: 50% IMDM and 50% F12 (Life Technolo-
gies) supplemented with 64 mg/l L-ascorbic acid 2-phosphate
Mg2+ salt (Sigma-Aldrich), 40 ml/l monothioglycerol (Sigma-Al-
drich), 8.4 mg/l additional sodium selenite (Sigma-Aldrich), 10 g/l
polyvinyl alcohol (Sigma-Aldrich), 13 GlutaMAX (Life Technolo-
gies), 13 nonessential amino acids (Life Technologies), 0.13
chemically defined lipid concentrate (Life Technologies),
10.6 mg/l Holo-Transferrin (Sigma-Alrich), and 20 mg/l insulin
(Sigma-Aldrich). Differentiation was conducted in a hypoxic con-
dition from day 0 to day 5, and then in a normoxic condition
fromday 6 to day 9 (Figure 1). The 13TrypLEwas used to dissociate
and collect cells for analysis.
MB, HB, and Hematopoietic CFC Assays
MB and HB were detected as described previously (Vodyanik et al.,
2010). Hematopoietic CFCs were detected using serum-containing
H4436 Methocult (Stem Cell Technologies) or serum-free H4236
Methocult with added FGF2 (20 ng/ml), SCF (20 ng/ml), IL-3
(10 ng/ml), IL-6 (10 ng/ml), and EPO (2 U/ml) as described previ-
ously (Choi et al., 2012).
Assessment of the Hematoendothelial Potential of
Differentiated hPSCs
Sorted day 4 or day 5 cultures were plated on a confluent layer of
OP9 cells in a-MEM (GIBCO) supplemented with 10% FBS (Hy-
clone) supplemented with 100 mM monothioglycerol, 50 mg/ml1082 Stem Cell Reports j Vol. 3 j 1073–1084 j December 9, 2014 j ª2014 Thascorbic acid, 50 ng/ml SCF, TPO, IL-6, and 10 ng/ml IL-3 at a den-
sity of 5,000 cells/well of a six-well plate as described previously
(Choi et al., 2012). Cultures were analyzed 4–7 days later by immu-
nofluorescent staining or by flow cytometry (Choi et al., 2012).
T Cell Differentiation of Day 9 Cultures
The OP9 cell line expressing human DLL4 (OP9-DLL4) was estab-
lished by using lentivirus expressing human DLL4 under the
EF1a promoter. After hPSC differentiation for 9 days, the floating
CD43+ cells were collected; strained through a 70 mm cell strainer
(BD Biosciences); resuspended in T cell differentiation medium
consisting of a-MEM (GIBCO) supplemented with 20% FBS (Hy-
clone), IL7 (5 ng/ml), FLT3L (5 ng/ml), and SCF (10 ng/ml); and
cultured on OP9-DLL4. After 4 days, the cells were harvested using
a collagenase IV (GIBCO) solution (1 mg/ml in DMEM/F12;
GIBCO) and 13 TrypLE (Life Technologies), and passaged onto a
fresh layer ofOP9-DLL4. After 3 days, the cells were passaged again.
Subsequent passageswere conducted every7days for up to4weeks,
and then floating cells were collected for flow analysis and
genomic DNA extraction for TCR rearrangement assay.
Statistical Analysis
Statistical analysis was performed using Microsoft Excel. Data ob-
tained from multiple experiments were reported as the mean ±
SE. A two-tailed Student’s t test was used to compare two groups.
Differences were considered significant when p < 0.01.
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